Pages that link to "Q28297680"
The following pages link to Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (Q28297680):
Displaying 50 items.
- Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus (Q24185805) (← links)
- Glucagon and heart in type 2 diabetes: new perspectives (Q26738580) (← links)
- The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer (Q26738873) (← links)
- Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence (Q26739999) (← links)
- Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion (Q26740171) (← links)
- Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development? (Q26740247) (← links)
- Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? (Q26740253) (← links)
- Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders (Q26740443) (← links)
- Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice (Q26741860) (← links)
- Diabetes Drugs and Cardiovascular Safety (Q26746085) (← links)
- Advances in the treatment of type 2 diabetes: impact of dulaglutide (Q26746220) (← links)
- The EMPA-REG outcome study: critical appraisal and potential clinical implications (Q26748742) (← links)
- The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials (Q26748870) (← links)
- Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals (Q26749176) (← links)
- Novel extrapancreatic effects of incretin (Q26749181) (← links)
- Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes (Q26749281) (← links)
- Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations (Q26749524) (← links)
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? (Q26750510) (← links)
- Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? (Q26752255) (← links)
- Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation (Q26752294) (← links)
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies (Q26765047) (← links)
- Incretin-Based Therapy for Prevention of Diabetic Vascular Complications (Q26765470) (← links)
- The metabolic vascular syndrome - guide to an individualized treatment (Q26767142) (← links)
- Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review (Q26767260) (← links)
- Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes (Q26767283) (← links)
- Do glucagonomas always produce glucagon? (Q26771665) (← links)
- Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus (Q26774021) (← links)
- New Insights in the Diagnosis and Treatment of Heart Failure (Q26774884) (← links)
- Drugs for type 2 diabetes: role in the regulation of bone metabolism (Q26775763) (← links)
- Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies (Q26777177) (← links)
- Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? (Q26777994) (← links)
- Vascular repair strategies in type 2 diabetes: novel insights (Q26778658) (← links)
- Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease (Q26781269) (← links)
- Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease (Q26784211) (← links)
- The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease (Q26784454) (← links)
- Incretin physiology and pathophysiology from an Asian perspective (Q26784623) (← links)
- Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes (Q26785454) (← links)
- What's next after metformin? focus on sulphonylurea: add-on or combination therapy (Q26786524) (← links)
- DPP4 in Diabetes (Q26797335) (← links)
- Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association (Q26798326) (← links)
- Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements (Q26801121) (← links)
- Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition (Q26801170) (← links)
- Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists (Q26823085) (← links)
- Origin and therapy for hypertriglyceridaemia in type 2 diabetes (Q26824004) (← links)
- Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients (Q26824239) (← links)
- Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications (Q26824616) (← links)
- Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence? (Q26827760) (← links)
- Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure (Q26829634) (← links)
- Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach (Q26851797) (← links)
- Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke (Q26861493) (← links)